Beech Hill Advisors Inc. Has $2 Million Stake in Pfizer Inc. (NYSE:PFE)

Beech Hill Advisors Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 2.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,914 shares of the biopharmaceutical company’s stock after selling 2,210 shares during the period. Beech Hill Advisors Inc.’s holdings in Pfizer were worth $2,000,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Impax Asset Management Group plc purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $713,000. FourThought Financial Partners LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $841,000. Finally, Denali Advisors LLC lifted its stake in Pfizer by 12.8% in the fourth quarter. Denali Advisors LLC now owns 37,100 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 4,200 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Price Performance

PFE stock opened at $24.29 on Thursday. The firm has a 50 day simple moving average of $23.38 and a two-hundred day simple moving average of $24.87. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a market cap of $138.10 billion, a PE ratio of 17.60, a P/E/G ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.08%. Pfizer’s dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.